Skip to Content
Merck
All Photos(1)

Documents

Safety Information

N-905

Supelco

Nordiazepam solution

1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H11ClN2O
CAS Number:
1088-11-5
Molecular Weight:
270.71
EC Number:
200-659-6
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

concentration

1 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Clc1ccc2NC(=O)CN=C(c3ccccc3)c2c1

InChI

1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)

InChI key

AKPLHCDWDRPJGD-UHFFFAOYSA-N

Related Categories

General description

Nordiazepam is a benzodiazepine prescribed for treatment of anxiety and panic attacks. This analytical reference standard is suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing applications. Nordiazepam is also a primary urinary metabolite of benzodiazepines diazepam and chlrodiazepoxide.

Application


  • Probe Electrospray Ionization Tandem Mass Spectrometry for the Detection and Quantification of Benzodiazepines: This study employs advanced mass spectrometry techniques to enhance the detection and quantification of Nordiazepam and other benzodiazepines, critical for therapeutic drug monitoring in clinical settings. This method ensures high sensitivity and specificity, improving pharmacokinetic studies of benzodiazepine metabolites (Griffeuille et al., 2024).

  • Selective Extraction of Diazepam and Its Metabolites from Urine Samples: Details a molecularly imprinted solid-phase extraction method, utilizing analytical grade Nordiazepam for benchmarking, to selectively extract diazepam and its metabolites from urine. This approach is pivotal for forensic and clinical toxicology, providing a reliable method for drug monitoring and abuse detection (Gil Tejedor et al., 2024).

  • Hair Analysis in Postmortem Investigations: Discusses the application of hair analysis in forensic science, where Nordiazepam and other drug residues are identified in postmortem samples. This technique is essential for determining drug involvement in unexplained deaths, offering insights into chronic drug use or poisoning (Pelissier-Alicot et al., 2024).

  • Diazepam: A comprehensive review of diazepam, detailing its pharmacology, therapeutic use, and metabolism, including Nordiazepam as a significant metabolite. This information is crucial for healthcare professionals to understand the effects, interactions, and potential side effects of this widely used benzodiazepine (2006).

  • Trace Analysis of Psychotropic Medications in Environmental Samples: Utilizes ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to detect low concentrations of Nordiazepam and other psychotropic medications in environmental samples. This research supports environmental health studies by tracking pharmaceutical pollutants, which can affect water sources and wildlife (Wang et al., 2024).

Recommended products

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

N-911

Nordiazepam-d5 solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

IMF-020S

iMethod Test Kit for Benzodiazepines with Synthetic Urine, kit of 23 × 1.0 mL ampules, certified reference material, Cerilliant®

D-902

Diazepam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-907

Diazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-910

Diazepam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-903

Nordiazepam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-080

Phenazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

F-047

Flubromazolam solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-159

Diclazepam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

D-160

Diclazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

D-163

Delorazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

FSL

Flammable liquids
Alcohols
Hazardous rank II

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

N-905-1ML:4.548173317977E12

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Craig Lehmann et al.
Journal of clinical pharmacology, 48(4), 436-444 (2008-02-02)
A diazepam 10-mg autoinjector was evaluated in bioequivalence and dose proportionality studies; both involved 24 young, healthy subjects and used randomized, open-label, 2-treatment, 2-period crossover designs with a 3-week washout period between treatments. The bioequivalence study compared a single diazepam
Shanlin Fu et al.
Journal of analytical toxicology, 34(5), 243-251 (2010-06-10)
beta-Glucuronidase is an enzyme often employed to de-conjugate beta-glucuronides during urinary drug testing for benzodiazepines. It is commonly accepted that use of beta-glucuronidase is a preferred method of hydrolysis over acid-catalyzed hydrolysis, which is known to induce benzodiazepine degradation and
David A Fishbain et al.
Pain medicine (Malden, Mass.), 10(3), 565-572 (2008-11-11)
The objectives of this medicolegal case report are the following: 1) to present details of a chronic pain patient (CPP) who was placed on chronic opioid analgesic therapy (COAT), and subsequently overdosed on multiple drugs, some of which were not
Ali Acikgöz et al.
Toxicology and applied pharmacology, 234(2), 179-191 (2008-11-06)
Drug biotransformation is one of the most important parameters of preclinical screening tests for the registration of new drug candidates. Conventional existing tests rely on nonhuman models which deliver an incomplete metabolic profile of drugs due to the lack of
Joris C Verster et al.
Sleep medicine reviews, 17(2), 153-159 (2012-08-14)
The use of benzodiazepine receptor agonists can significantly impair driving performance. The aim of this review was to determine if there is a relation between blood concentrations of these drugs and the degree of driving impairment. A literature search was
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service